Cambridge-based Tuune developer Uniq Health Ltd raises £100.1k

Uniq Health Ltd has secured £100.1k in a new funding round to support its personalized healthcare platform for women. Trading under the name Tuune, the Cambridge-based company specializes in hormonal intelligence and uses a proprietary algorithm to help users identify suitable medications. The platform analyzes individual medical histories and side effect profiles to provide these recommendations.

Founded in 2017, the company operates within the natural sciences and engineering research sector. Its latest financial accounts for the year ending 31 December 2025 indicate a team of three employees.

This latest injection of £100.1k (allotted in April 2026) follows several previous funding rounds. In March 2023, the company raised £100k. Prior to that, a March 2021 round of £100k was completed at a valuation of £41.6k. This followed an April 2020 round where the company raised £121.6k at a valuation of £1.3m. The earliest recorded round in April 2019 saw the firm raise £20k at a valuation of £68k.

The company focuses on solving the problem of trial-and-error in women’s healthcare, specifically regarding hormonal treatments. By leveraging its algorithm, Tuune aims to reduce the adverse effects often associated with generic prescriptions. Total funding across these recorded rounds now exceeds £440k.